Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Astek Diagnostics Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single action is being handled by 1 distinct examiner, CELSA, BENNETT M. The company's active prosecution is concentrated within 1 distinct art unit, reflecting a targeted technical scope for its current diagnostic filings. This allows for a prosecution strategy that is highly specific to the requirements of that art unit.
CELSA, BENNETT M is the busiest examiner for the portfolio, accounting for 1 busiest examiner pending action. This represents the entirety of the company's current workload at the patent office. The alignment of 1 pending office action with 1 distinct examiner indicates a centralized prosecution effort. This structure allows the company to focus its resources on a single set of examiner feedback and expectations.
The involvement of only 1 distinct art unit means the company is operating within a specific regulatory and technical environment. With 1 pending office action, the portfolio is currently in a manageable and focused state. Practitioners can work closely with CELSA, BENNETT M to address the specific concerns raised in the action. This profile illustrates a company with a very specialized focus within the broader biotechnology sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CELSA, BENNETT M | 1 | 33.3% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18765978 | Method and Device for Detecting Presence, Concentration, and Antibiotic Resistance of Bacteria in Urine Samples | CELSA, BENNETT M | — |
| Art Unit | Apps |
|---|---|
| 1600 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18765978 | Method and Device for Detecting Presence, Concentration, and Antibiotic Resistance of Bacteria in Urine Samples | CELSA, BENNETT M | 1600 | §103§112 | Non-Final OA | — | Pending | Jul 08, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAstek Diagnostics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Bennett M Celsa has the most, with 1 of Astek Diagnostics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
